Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Artificial Intelligence: US FDA Plans Guidances On Algorithm Bias, Product Development

Mar 21 2024

• By Derrick Gingery

artificial intelligence — • Source: Shutterstock

Related Content

AI In Drug Development: FDA Wants To Know How To Assure Data Integrity, Transparency, Reliability

May 11 2023

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Feb 03 2023

EMA, US FDA Worry About AI’s Pitfalls And Promises

Jul 24 2023

Artificial Intelligence Oversight At FDA Will Require Continuous Algorithm Validation, Califf Says

Feb 13 2024

Artificial Intelligence: Industry Wants FDA To Boost Access To Databases, Clarify Use In Assessing Drug Efficacy

Sep 07 2023

Rise Of The Machines: FDA Artificial Intelligence Guidance Is Coming

Apr 02 2019

FDA Issues 5-Point Action Plan For Artificial Intelligence/Machine Learning-Based SaMD

Jan 12 2021

VeriSIM Expects AI Use To Trim Margin For Failure In OTC Switches, Help Boost Revenue Margins

Mar 21 2024

When Using Artificial Intelligence In Pharma R&D, Start With Identifying Problem To Solve

Mar 21 2024

Additional Topics

United States Artificial Intelligence Research & Development Regulation BioPharmaceutical

More from Digital Technologies

More from HBW Insight

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window